首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Portal, splenic and mesenteric vein thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation
【24h】

Portal, splenic and mesenteric vein thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation

机译:患者双重杂合体中的门静脉,脾和肠系膜静脉血栓形成,凝血因子V莱顿和凝血酶原G20210A突变

获取原文
获取原文并翻译 | 示例
       

摘要

We herein report a 56-year-old man who presented with abdominal pain, diarrhea and a 22-kg-weight loss over 4 months. He was on acenocoumarol treatment because of portal, splenic and mesenteric vein thrombosis (PSMVT) 3 months before, with admission international normalized ratio (INR):1.6. Doppler ultrasonography and helical computerized tomographic scan of the abdomen showed complete thrombosis of the extrahepatic portal vein extending into the superior mesenteric vein and splenic vein. The manifestation of thrombosis was in the absence of provocative stimuli or local cause. The patient had a negative history of venous thromboembolism. Thrombophilia workup revealed double heterozygosity for factor V Leiden and prothrombin G20210A mutation. He was immediately started with intravenous unfractionated heparin, followed by oral anticoagulation with target INR 2-3. Five days after a Doppler examination showed significant improvement in the flow within the portal vein, and a computerized tomographic scan of the abdomen 1 month later showed extensive recanalization of the portal venous system. The patient is now 36 months out from the second PSMVT episode and is doing well although maintaining oral lifelong anticoagulation. The case is of particular interest in that PSMVT was the first manifestation of this combined disorder. We conclude that all patients presenting with unexplained PSMVT should be investigated for the presence of a hypercoagulable state. Anticoagulation should be considered in all patients with this diagnosis and should be a lifelong therapy in those with an underlying thrombophilia.
机译:我们在这里报告了一个56岁的男人,他在4个月内出现腹痛,腹泻和22公斤体重的减轻。他在3个月前因门静脉,脾和肠系膜静脉血栓形成(PSMVT)而接受乙酰香豆酚治疗,入院国际标准化比率(INR):1.6。腹部多普勒超声检查和螺旋计算机断层扫描显示,肝外门静脉完全血栓形成,延伸至肠系膜上静脉和脾静脉。血栓形成的表现是在没有刺激性刺激或局部原因的情况下。该患者有静脉血栓栓塞阴性史。血栓形成检查显示V因子Leiden和凝血酶原G20210A突变具有双重杂合性。立即开始使用普通肝素静脉注射,然后口服抗凝,目标INR 2-3。多普勒检查后五天显示门静脉内的血流明显改善,并且在一个月后对腹部进行计算机断层扫描显示门静脉系统的广泛再通。该患者距第二次PSMVT发作已经36个月了,并且尽管维持口服终生抗凝治疗,但情况良好。该病例特别令人感兴趣,因为PSMVT是这种合并疾病的首发表现。我们得出的结论是,应对所有出现无法解释的PSMVT的患者进行高凝状态调查。所有具有这种诊断的患者都应考虑抗凝治疗,并且对于有潜在血栓形成倾向的患者应作为终生治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号